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ABSTRACT
Background: Antenatal adherence to aspirin prophylaxis is key to
reducing the occurrence of a major pregnancy complication: pre-
eclampsia (PE). Up to 75% of pregnant women at increased risk
of pre-eclampsia do not take aspirin as prescribed. Little research
has been done to understand the psychological determinants of
aspirin adherence in pregnancy. This qualitative study aimed to
explore barriers and facilitators to aspirin adherence in women at
increased risk of PE using version 2 of Theoretical Domains
Framework (TDF).
Methods: Fourteen women from the North-East of England who
declared various levels of non-adherence to aspirin (0–5 of 7
prescribed tablets/week) were interviewed 4–18 months after
delivery, using the TDF as a guide. Semi-structured interviews
were digitally recorded and transcribed verbatim. A thematic
framework analysis was used.
Results:Women exhibited both intentional and unintentional non-
adherence and faced multiple barriers at a personal and
environmental level. They struggled to initiate, implement and
persist in taking medication as prescribed. Women expressed
inadequate knowledge about PE and aspirin; they struggled to
identify as ‘medication takers’ and relate to the risk factors for PE
as identified by the midwife. Significant barriers within the
health-care environment were identified; women had difficulties
obtaining medication and perceived conflict amongst health care
professionals regarding medication safety.
Conclusion: A combination of inadequate knowledge, lack of
identification with the risk factors and beliefs about
consequences of taking medication were interlinked with other
domains, such as environmental context and resonate with the
Necessity-Concerns Framework.
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Introduction
Pre-eclampsia (PE) affects 2–5% of all pregnancies (Duley, 2009) and can lead to devas-
tating outcomes; it is the second leading cause of maternal death (Saving Mothers’ Lives,
2011) with an estimated global death toll of 60,000 women per year (Khan, Wojdyla, Say,
Gülmezoglu, & Van Look, 2006). Short-term healthcare costs of caring for a mother and
baby affected by PE are double those of uncomplicated pregnancy with an excess cost of
€2791 per pregnancy (Fox et al., 2017). Mothers affected by PE are more likely to develop
cardiovascular disease later in life (Yinon et al., 2010) while offspring are also at risk of
developing long-term morbidity (Vatten et al., 2003).
Globally low-dose aspirin is used to reduce the risk of PE. In the World Health Organ-
isation (WHO) recommendations for the prevention and treatment of pre-eclampsia,
daily low-dose aspirin is featured as recommended strategy for prevention of PE,
(WHO, 2011) while the American College of Obstetricians and Gynecologists (ACOG)
suggests 81 mg of daily aspirin to women at risk of PE (WHO, 2011). In line with the
NICE guideline ‘Hypertension in pregnancy: diagnosis and management’ (ACOG Prac-
tice Bulletin, 2019); in England, women with one major risk factor (chronic hypertension,
previous PE, Type 1/Type 2 diabetes mellitus, autoimmune and chronic kidney disease)
or more than two minor risk factors (first pregnancy, family history of PE, body mass
index (BMI) of ≥35 kg/m2, multiple pregnancy and age ≥40 years) are considered to
be at higher risk of PE and are offered prophylactic aspirin therapy (National Institute
for Health and Care Excellence, 2019) (75–150 mg taken at bedtime). This is based on
high-quality evidence of the effectiveness of a low-dose aspirin for the prevention of
PE when started before the 16th week of pregnancy (Roberge et al., 2017a). The
results of a recent international RCT of 150 mg of aspirin vs placebo showed a reduction
in the incidence of early onset of PE in the aspirin group without increasing the risk of
adverse effects (Rolnik et al., 2017a).
In the group of pregnant women at increased risk of PE, non-adherence to aspirin may
play a pivotal role in the variability of response to treatment (Vinogradov et al., 2020). A
recent subgroup analysis of the ASPRE trial (a randomised controlled trial (RCT) of
150 mg of aspirin to prevent PE) reported the effectiveness of the treatment ranged from
40% in the cohort with adherence of <90% to 75% in those with adherence >90% (Wright
et al., 2017). The non-adherence rate to aspirin prophylaxis in pregnancy was suggested
to range between 21.4% and 46.3% (Abheiden et al., 2016), which is equivalent to the medi-
cation non-adherence rates in non-pregnant patients with chronic disease. However, a
recent study suggests that non-adherence to aspirin during standard clinical care may be
as high as 75% amongst women at increased risk of PE (vanMontfort et al. 2020). Therefore,
improving adherence to aspirin in this cohort is crucial to optimise outcomes.
Previous studies of women’s perception of medicine use in pregnancy suggest that
women are more likely to avoid the use of medicine during pregnancy due to safety con-
cerns (Nordeng, Ystrøm, & Einarson, 2010) and this is exacerbated by the presence of
conflicting information on the internet and insufficient support fromhealth care providers
(Ceulemans, Van Calsteren, Allegaert, & Foulon, 2019). Women are more likely to take
medicine if they perceive that their medical condition poses a threat to their fetus
(Nyholm, Andersen, Vermehren, & Kaae, 2019).Womenmay view aspirin therapy differ-
ently in pregnancy because of its prophylactic use to prevent the onset of PE, rather than
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the treatment of symptoms of an established disease. Lin et al explored an extended theory
of planned behaviour (with addition of action planning, coping planning and relationships
with husband) to explain aspirin adherence in pregnant women (Lin, Broström, Nilsen, &
Pakpour, 2018). The study supported the proposed theory; however, it could not demon-
strate casual relationships amongst variables and no association between subjective norms
and intentions to perform the behaviour was found. Although the theory of planned
behaviour has been recognised for its contribution to the development of behavioural
sciences, it is heavily criticised for its parsimonious approach, limited validity and
utility (Sniehotta, Presseau, & Araújo-Soares, 2014). In a recent qualitative study of
aspirin use amongst pregnant women (n = 6) only one barrier (pill burden) and one facil-
itator of aspirin adherence (relationship with health care provider) were reported (Shan-
mugalingam et al., 2020). Although literature on psychological determinants of non-
adherence to aspirin treatment is scarce, personal characteristics such as maternal age,
smoking status, level of education, parity, ethnicity, and previous history of PE are
known to be associated with non-adherence to medication in pregnancy (Ceulemans
et al., 2019; Lupattelli, Spigset, & Nordeng, 2014; Wright et al., 2017).
As non-adherence to aspirin prophylactic therapy in pregnancy, is likely to be
complex and multifaceted, and having little evidence from other qualitative research
in this area, we decided to adopt a wider theoretical approach and to apply qualitative
methodology to gather an in-depth understanding of this phenomenon (non-adherence
to aspirin in pregnancy).
To synthesise psychological determinants of non-adherence to aspirin in pregnancy the
TheoreticalDomains Framework (TDF) can be used. TheTDFwas developed as an overarch-
ing framework that integrates behaviour enactment and change theories under a series of
domains. The TDF is based on behaviour change theories andmodels, with the factors associ-
ated with behaviour and behaviour change. This framework has been used to identify modifi-
able barriers, enablers andenactment tobehavioural change, aswell as todevelop theory-based
behaviour change interventions (Francis, O’Connor, &Curran, 2012;Michie et al., 2005). The
refined framework, containing 14 domains (subsuming 84 constructs (Cane, O’Connor, &
Michie, 2012; Francis et al., 2012), has been widely used for behaviour change research
across a range of clinical situations (Birken et al., 2017). However, the TDF has not been
used to explore factors affecting adherence of pregnant women to prescribed aspirin. Identifi-
cation of modifiable components of the behaviour may facilitate the development of more
effective interventions to increase adherence tomedication in the future (Araújo-Soares,Han-
konen, Presseau, Rodrigues, & Sniehotta, 2019).
The aim of ‘Aspirin non-adherence in pregnancy – ANA’ study was to gain an in-
depth understanding of the reasons for women’s non-adherence to prophylactic
aspirin prescribed during pregnancy, by identifying modifiable barriers and facilitators
of medication adherence in women at risk of preeclampsia, using the TDF.
Methods
A qualitative study using semi-structured interviews based on the TDF was conducted.
An interview guide was developed, based on the refined TDF (Cane et al., 2012) and sub-
sequently modified following a review by an independent group of women (see interview
guide in supplementary materials, Appendix 1).
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Population
Participants recruited from an ongoing study ‘Wave’ (trial registration number
ISRCTN41944844), who consented to be contacted for the purposes of further research
and disclosed adherence levels ≤5 aspirin tablets per week (out of 7 prescribed) at the
time of the 20-week scan, were given the opportunity to participate. Women who experi-
enced perinatal loss were not approached.
Out of 52 women meeting non-adherence criteria, 20 women expressed wiliness to
participate. We purposively selected women with the lowest levels of adherence to
enable us to identify barriers to adherence. We also endeavoured to include participants
from different social backgrounds, with diverse risk factors, parental experience and age
(see participant’s characteristics in Table 1 and Figure 1 [recruitment diagram]).
Although an additional six women expressed an interest in taking part in the study,
data collection was stopped following the analysis of 14 interviews, as data saturation
was achieved, as agreed at a research meeting. Interviews were conducted 4–18
months following the delivery of the baby (mean 9.4 months). All participants were
from North-East of England.
Ethical considerations
The study was reviewed and given a favourable opinion (NHS REC ref 19/NI/0139). All
women gave informed written consent to participate in the study.
Table 1. Participant demographics.
Participant
Adherence
level Ethnicity Age Edu Parity
Child’s
age Risk factor
ANA 1 0/7 WB 31 10 3 14 m BMI + Fh
ANA 2 0/7 WB 40 13 2 18 m BMI, CHPT, PIH,
SGA, Interval
ANA 5 0/7 Mixed 41 25 0 13 m BMI, P0
ANA 7 0/7 WB 23 11 1 4 m PE
ANA 10 0/7 WB 24 9 1 8 m BMI, PE
ANA 11 0/7 WB 36 13 1 4 m BMI, Interval
ANA 14 0/7 WB 33 18 1 7 m PIH?PE
ANA 4 1/7 WB 40 13 0 6 m P0, Fh
ANA 6 3/7 WB 29 11 1 12 m PE, Fh
ANA 8 4/7 WB 31 14 2 7 m T2DM
ANA3 5/7 WB 33 18 1 11 m PE, SGA
ANA 9 5/7 WB 36 22 1 15 m PIH, Fh
ANA 12 5/7 WB 24 16 0 8 m T2DM, P0
ANA 13 5/7 WB 24 15 0 4 m BMI, P0











Notes: Adherence expressed in number of pills taken over 7 days preceding 20 weeks visit.
Ethnicity: WB – with British.
Education expressed as number of years in full time education.
Parity number of livebirths at the time of the index pregnancy.
Child age expressed in month and reflect the time lag since the end of the index pregnancy.
Risk factors: PE – pre-eclampsia in previous pregnancy, BMI – Body Mass Index > 35 kg2/cm, Fh – family history of PE,
CHPT – Chronic hypertension, PIH – pregnancy induces hypertension, SGA – small for gestational age infant, Interval
– Pregnancy interval > 10 years, P0 – no previous livebirths over 24 weeks gestation, PIH – pregnancy induces hyper-
tension in previous pregnancy, T2DM – Type 2 Diabetes Mellitus.
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Researcher’s characteristics
Interviews were conducted by a trained researcher (RV). RV (BA, M Clin Res) is a female
senior research sonographer and was the lead researcher for both the ‘Wave’ and ‘ANA’
studies and therefore had an opportunity to meet participants and establish relationships
as a researcher. There was at least a 9-month interval between the Wave and ANA study
visits. All participants were aware of RV’s research role. The rest of the research team had
no contact with the participants and had only access to the anonymised transcripts for
the purposes of data analysis and to assure quality.
Data collection
Women were offered an option to be interviewed in person, by phone or using Skype.
Duration of the interviews varied from 1 to 2 h. Women were asked to provide a narra-
tive regarding their experiences of aspirin use (or non-use) and were then guided by the
interviewing researcher to discuss specific aspects of their experiences (as per the inter-
view guide) if not previously mentioned by participants. The duration of individual inter-
views was determined by the quantity of information women were willing to share.
Length of each interview was also influenced by participant personal characteristics
such as communicativeness and by the relevance of questions to women’s experience
i.e. in cases where women have experienced intentional non-adherence (decided not to
take aspirin) questions regarding their experience with aspirin intake were omitted.
No repeat interviews were performed. Interviews were audio-recorded and tran-
scribed verbatim. Field notes were collected and used to assist researchers to immerse
in the data. Transcribed interviews underwent participant checks and were anonymised.
Data were managed using NVIVO 12.
Figure 1. Recruitment diagram.
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Analysis
As we aimed to describe and interpret what is happening in particular settings, i.e. what bar-
riers and facilitators women face in adherence with aspirin, a thematic framework analysis
(TFA) was selected to analyse the data. TFA is set to answer a specific question (to understand
barriers and facilitators of adherence), it is appropriate to be conducted within a limited time-
frame, uses a pre-designed sample and addresses a priori issues (Araújo-Soares et al., 2019).
TFA was conducted using five analytical stages: familiarisation, identifying a thematic frame-
work, indexing, charting, and mapping and interpretation (Araújo-Soares et al., 2019; Srivas-
tava, 2009). As both the interview guide and the framework were constructed using the TDF,
care was taken to perform inductive data coding first to ensure all themes were identified.
Once coded, data were sorted into the thematic framework (see final coding frame in Appen-
dix 2). Analysis of the interviews was conducted by xx and xx in parallel with data collection.
During this period, research clinics were held regularly amongst the members of the research
team (RV, VS, VAS, SV) with the aim to review coding, the framework, to resolve disagree-
ments, and to identify data saturation as it emerged.
Results
The results presented in this section under each of the TDF domains can be examples of
either barriers or facilitators of adherence. A selection of representative quotes is pro-
vided to illustrate the domains and relevant constructs within the domain (see Appendix
3, Table 2 and Table 3 for a wider selection of quotes representing barriers and facilitators
to adherence in this cohort).
Types of non-adherence
Women exhibited both intentional and unintentional non-adherence.
In the case of intentional non-adherence some women made an explicit decision not
to take aspirin as prescribed:
If I was given a prescription, I must have put it straight in the bin. ANA 14 (33 yo, P1, prev
PE, 0/7)
Others implied that they had no intention to take it:
I haven’t even got the prescription yet. I kept saying I’ll get it tomorrow. I didn’t think I need
it, so I didn’t take it. ANA 1 (31 yo, P3, BMI + Fh, 0/7)
Some women made a decision to take aspirin, but struggled to keep up with the regular
medication schedule i.e. exhibited unintentional non-adherence:
Sometimes a day would go past, and I would realise I hadn’t taken it. And it wasn’t really so
much because I didn’t want to or because I didn’t understand why. ANA 3 (33yo. P0, PE,
SGA, 4/7)
Intentions dictated the type of non-adherence exhibited by women (intentional vs unin-
tentional). However, participants’ intentions were subject to change across time, making
the distinction between intentional and unintentional adherence difficult; some women
did not make an attempt to review their initial intention about whether to take aspirin,
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whilst others changed their intentions in response to environmental and/or physiological
events, further independent learning or interactions with health care providers.
Determinants of non-adherence as defined by medication taking
processes
Women’s narratives fed into three main themes aligned to medication taking processes
(Vrijens et al., 2012) (see Table 4 in Appendix for summary of the themes):




Decisions regarding aspirin were based on a very fine balance of beliefs held by women about
the necessity of the medication and their concerns regarding the use of aspirin during preg-
nancy. Domains such as Knowledge (poor knowledge about PE), Identity (lack of identity
with at risk group), Social Influence (not a social norm), Optimism (unrealistic optimism),
and Reinforcement (lack of active reinforcement) contributed to a sense of low necessity to
take aspirin. Concerns were fortified by domains such as Knowledge (poor knowledge related
to medication), Beliefs about consequences (concerns about effects of aspirin on both the
mother and a baby), Environmental context (perceived interprofessional disagreement).
Necessity
Participants demonstrated limited knowledge about pre-eclampsia and the potential con-
sequences of developing the condition. They discussed having and wanting to maintain
an optimistic outlook about the progression of their pregnancy and held misconceptions
about the potential benefits of taking aspirin as a preventative medication, which led to
women having a reduced sense of necessity about taking aspirin.
The degree of knowledge about PE varied depending on whether women had been
diagnosed with the condition previously (had experiential knowledge), knew someone
who had the condition (vicarious knowledge) or had theoretical knowledge (had heard
or read about it).
Pre-eclampsia… I’ve heard of it. It is not where the placenta blocks the birth passage or
something like that… I’ve heard of it… I never really… no… ANA 2 (40 y/o, P2,
multip risks, 0/7)
It’s a blood thinner isn’t it? I am assuming it keeps your heart pumping at the right level and
your blood pressure down. ANA 4 (40 y/o, P0 + Fh, 0/7)
I think I had good feeling that it was just never going to happen. I just didn’t think I would
ever have pre-eclampsia. ANA 12 (24 y/o, P0, T2DM, 5/7)
Experiencing a low sense of necessity to take aspirin was exacerbated by a lack of personal
identification with the risk factors identified by health care professionals. This manifested
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in women not recognising the need to take the medication. For some women, an inability
to relate to the PE-related risk factors discussed by health professionals led to strong
negative reactions to being classified as having a ‘high-risk’ pregnancy as women felt stig-
matised by attributingto their labels.
I wouldn’t say it’s got anything to do with your weight personally cos it can happen to
anyone like the thinnest of people can have really high blood pressure and have blood
clots. So, I think they put the stigma on people that are overweight. Everyone’s different.
ANA 11 (36 y/o, P1, BMI+ interval, 0/7)
For some women, this was also influenced by the fact that they regarded themselves as
someone who does not easily resort to taking medicines. Even women with underlying,
chronic medical conditions seemed unable to identify themselves as ‘medication takers’.
I don’t like taking medicine, but I don’t even like taking paracetamol for headaches and stuff.
No, it was fine I can take it I just, I don’t like my body relying on medicine. Like if I’ve got a
headache, I don’t like taking paracetamol I’d rather my body gets rid of it on its own. ANA 7
(23 yo, P1, prev PE, 0/7)
I felt like, I felt like a pill bottle: if you shake me, I would rattle. Cause I don’t really take
medication. If I have a headache, I don’t like go and take paracetamol straight away. I’d
put up with it for a while before I took anything for it. ANA 8 (31 yo, P2, T2 DM, 4/7)
Furthermore, women made a clear distinction between the benefits of taking aspirin
and other preventative medicines such as folic acid and vitamin D. Vitamins were viewed
by women as an essential support to a growing fetus and commonly used, whereas,
aspirin was perceived as an uncommon medication to use during pregnancy with little
or doubtful benefit.
When you take your folic acid, you are taking the folic acid for the baby -you are not taking
it for you… It’s drummed into you and everything you read… you are good mum if you
take your vitamins sort of thing, whereas the discussion about aspirin is not, well… it
didn’t feel like it was about that. It was about keeping the mum healthy and it’s the
same with lots of medication. If people don’t feel like there are going to get a benefit
from it especially a non-visible benefit from it then what’s the point? ANA 14 (33 yo,
P1, prev PE, 0/7)
She (a friend) told me she hadn’t really been taking them, only in hospital. So, she didn’t
know the benefits of taking them. ANA 8 (31 yo, P2, T2 DM, 4/7)
Interviews highlighted a perceived lack of professional support and reinforcement of
the importance of aspirin adherence at the most crucial times during pregnancy, such as
at the start of aspirin prescription or at the time of significant events. Furthermore, some
women experienced a lack of coherence between hospital and community antenatal care.
The midwives didn’t want to take any responsibility over that. They are quite happy to push
vitamins folic acid. But whereas if you had a midwife saying this is good for your baby and I
am going to push this. And your community midwives that you had built a relationship with
then you might see it slightly differently and take it differently. But it was very… in my
experience very much a, that’s a hospital decision… very separate… Considering there
was one person being looked after and I am same person whether I am in the hospital or
with a community midwife there were very different agendas, very different agendas.
ANA 14 (33 yo, P1, prev PE, 0/7)
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In addition to the complexities described above, the decision-making process was com-
plicated by the restricted timeline of pregnancy, in particular the short interval between
women discussing the option of aspirin prophylaxis with an obstetrician and needing to
make a decision about whether to take aspirin. This was dictated by a need to start aspirin
early in pregnancy (by week 16) in order for it to be effective. Women also mentioned
there was an ‘information overload’ (or a cognitive overload) during consultations
with obstetricians and midwives, preventing women from being able to effectively con-
sider the relevant issues and make an informed decision.
You don’t have time to kind of like go through it all because you don’t know what that’s
going to say. So initially you’d say yeah okay then but kind of like go home you sit downright
okay what am I doing I’m taking this right what does it say, what is it for, what is, what does
it do. ANA 5 (41 yo, P0, BMI, 0/7)
Concerns
A number of concerns were raised by participants about the effects of aspirin intake
related to both maternal and fetal health.
I think one risk I didn’t really get to grips with would be the increased risks of like in terms of
haemorrhage and bleeding and stuff if you are on aspirin… But as a lay person, I can image
if I take that aspirin does that mean I am going to bleed more when I have my baby. ANA 14
(33 yo, P1, prev PE, 0/7)
I wasn’t wanting to take them in case like she got addicted… . I was concerned about heart
defect or something, but I didn’t actually question it. ANA 8 (31 yo, P2, T2 DM, 4/7)
Women revealed experiencing mixed messages from health care professionals regard-
ing aspirin intake during pregnancy and perceived it as a disagreement amongst health
care professional regarding the safety of aspirin use in pregnancy. An apparent lack of
agreement between health care professionals about the safety of aspirin seemed to
increase women’s concerns further and contributed to women exhibiting intentional
non-adherence to the prescribed medication.
Do you know there’s obviously some kind of risk as to why, if it was that good for you if
you’re high risk why would the pharmacies like not be willing to sell you aspirin when
you’re pregnant? So, there’s some kind of, do you know what I mean? ANA 11(36 y/o,
P1, BMI+ interval, 0/7)
I just went to the GP’s and told them that I had ran out and asked them if I could have some
more on a repeat prescription and they told us I couldn’t because I was pregnant […] No,
cos I kind of knew that you weren’t (supposed to take it) cos it’s written on the box. So, I
knew you weren’t allowed to take it. ANA 7 (23 yo, P1, prev PE, 0/7)
Further concerns were reinforced by the presence of conflicting online information
accessed by women when seeking information independently:
I did read a forum cos I’d Googled aspirin during pregnancy and there was a lot of mixed
people. Some people were like oh yeah it’s gonna help your pregnancy you know if you’re
high risk then other people were saying well actually I don’t really feel that good and I feel
quite uncomfortable taking it when they say you shouldn’t be taking stuff like during your
pregnancy. And someone had actually wrote the same thing that I thought why pharmacies
are reluctant to give aspirin to pregnant people. ANA 11 (36 y/o, P1, BMI+ interval, 0/7)
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Implementation
Once a fine decisional balance was reached, women who decided to take aspirin were
facing further barriers that contributed to non-intentional adherence.
A very prominent environmental barrier, reported in most of the interviews, related to
access to medication itself. Having no medication to hand may be one of the key factors in
unintentional non-adherence, as no matter how determined women are, if they have no
access to medication, they are unable to take it. This occurred because of challenges in
obtaining a prescription or collecting medication in a straightforward and timely manner.
Environmental barriers within the hospital context meant that some women left the
hospital without medication and were unable to obtain it until their next hospital visit,
usually 8 weeks later. Some women continued to face this challenge as they struggled
to replenish medication through repeat prescription or by getting it from the
pharmacy.
Yeah, I got the prescription on the day I had my 12 weeks scan and I took it to the pharmacy
and they said it wouldn’t be available until the next day and at that point I lived in xxx and I
didn’t have any way to get there and I never ended up picking it up honestly… until… I
can’t remember. I think it was after my 20 week and I started the aspirin a couple of days
before my 20-week scan, so that was my reason of not taking it, up until 20 weeks. ANA
13 (24 yo, P0, BMI, 5/7)
(Replenishing medication) it was really difficult. I took it to the doctors, but they didn’t put it
on the prescription, so I then I had to ring up my hospital too and get my medication cos the
doctors didn’t have it on their system. This happened a couple of times to be honest and I
did go without medication for a few days because like it was so much of a hassle to try and
get it… . ANA 8 (31 yo, P2, T2 DM, 4/7)
Poor memory and attention seemed to form another major barrier to unintentional
non-adherence. Women felt that their ability to focus during pregnancy was affected,
referring to this as ‘pregnancy fog’. Women suggested that lack of habit, forgetfulness,
physical and cognitive overload were the main reasons for missing their medication,
while lack of symptoms of the disease and consequently no sense of symptoms relief con-
tributed to unintentional non-adherence.
It was more to the end of my pregnancy when I started missing them. I was getting too tired
and I was just going to bed and forgetting. ANA 6 (29 y/o, P1, prev PE + Fh, 3/7)
I think, perhaps, I am not in very much in the habit of taking things. So sometimes a day
would go past and I would realise I hadn’t taken it. It was just that the day had gone pas
and in all its business and general kind of chaos, sometimes, with my eldest and I just
hadn’t got to the point where I did manage to take it. Perhaps simply because I am not
in a habit of taking it […] no symptoms would arise if I didn’t take it, kind of thing. For-
getting it didn’t lead to any incident’s kind of… or symptoms I suppose, which would make
you to have the medicine. ANA 3 (33yo. P0, PE, SGA, 4/7)
Many women lack regular medication taking experience as they have either not taken
regular medicines before or never mastered this skill and had low beliefs about their
capabilities to do so.
I am not really a tablet person. ANA 10 (24 yo, P1, Prev PE + BMI, 0/7)
I always found taking medication quite difficult. ANA 13 (24 yo, P0, BMI, 5/7)
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I’m no good at taking tablets even the folic acid tablets and stuff I didn’t really take them.
Yeah, I think I’m just generally bad at taking tablets [… ] I would give it a go but I
would probably be the same… ANA 7 (23 yo, P1, prev PE, 0/7)
Discontinuation
Critical incidents were often responsible for women discontinuing aspirin, creating a
novel state of intentional non-adherence or reducing the levels of motivation to
adhere. Events such as a change in their medical condition, significant social issue
such as housing problems and loss of a family member were coded as critical incidents
affecting adherence.
But it was I think when I got there (to the hospital) and it was the bleed, it (aspirin) wasn’t the
first thing that came to my mind. It was when they started asking me questions about what I
take, what I was doing, you know… you kind of like go back and go; right, okay, I was asleep,
so there’s nothing there…What do I take? They’re like: aspirin, why do you take aspirin? And
I told them. And I was like, right, okay, and then it came to me, you know, it’s a blood thinner
duh, duh, duh, duh, duh, duh and then you start. ANA 5 (41 yo, P0, BMI, 0/7)
I lost my sister when I was 8 weeks pregnant and that was a very strange one because none of
my family knew, so dealing with that was a bit intense. I think the worst things that could
happen, we also had to move out of our flat… ANA 13 (24 yo, P0, BMI, 5/7)
In instances related to a change in medical condition, some women in this cohort
proactively sought additional information related to use of aspirin, and although we
found no apparent evidence of reinforcement of adherence to aspirin from health care
professionals, there was evidence of unconditional support from relatives, irrespective
of womens’ decision about whether to take aspirin or not.
… the only person I’d spoke to was my partner and he said you know your body and you
know what’s right for you and he says so if that’s what you want to do then I support what-
ever you want. And he said only you can make the choice if you’re not happy taking it then
don’t take it. He says there’s plenty of women that go through pregnancies and don’t take it.
ANA 11(36 y/o, P1, BMI+ interval, 0/7)
Facilitators of adherence
TDF domains Skills and Behaviour regulation seemed to facilitate adherence behaviours
amongst some of the women with unintentional non-adherence.
Women who had previously taken prenatal vitamins or oral contraceptive pills found
the skills associated with taking those transferable and useful in taking aspirin.
So, it wasn’t a major obstacle, do you know what I mean it wasn’t a hindrance to have aspirin
cos I was already taking my vitamin D, so it was just an extra thing to take. ANA 11 (36 y/o,
P1, BMI, interval, 0/7)
In addition to developing a routine, some women also used reminders, calendars and pill
boxes to support adherence and establish new routines/habits, reducing unintentional
non-adherence.
He (partner) went out to Asda and brought a medicine box and he used it every Sunday and
fill it up so that everything was in for the days and times that I needed it. ANA 12 (24 y/o, P0,
T2DM, 5/7)
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Summary of the findings
Women exhibited both intentional and unintentional non-adherence to aspirin use
during pregnancy. Barriers to adherence were identified in all the domains conceptual-
ised within the TDF, however the domains of ‘Knowledge’, ‘Social (and professional) role
and identity’, ‘Optimism’, ‘Environmental context and resources’, ‘Social influence’, and
‘Beliefs about consequences’ seemed to dominate, indicating that women seem to con-
stantly negotiate necessity beliefs and concerns regarding the use of aspirin within the
healthcare system which is inadequately adapted to women’s needs in relation to sup-
porting adherence.
Women often knew surprisingly little about PE or prophylactic therapy with aspirin.
At the same time women did not see themselves as ‘medication takers’ and could not
identify with the PE-related risks ‘assigned’ to them. It seems that little understanding
of the condition, the possibility to prevent it, an inability to identify with the risk
factors and an optimistic outlook of the pregnancy led to a feeling of reduced need to
engage in preventive behaviours, namely the intake of aspirin. This can be seen by
data collected and presented around the domains Knowledge, Social Role and Identity
(Identity) and Optimism (unrealistic), leading to a weak sense of necessity.
There were also barriers inherent to the system. Once prescribed aspirin, women faced
multiple environmental barriers within the hospital and in the community, precluding
them from simply obtaining the medication.
Although, aspirin is prescribed by a consultant obstetrician within hospital setting,
women were questioned again, when interacting with other health care professionals
(such as pharmacists and general practitioners) and asked whether they really needed
to take it. Women perceived those mixed messages as intragroup conflict amongst
health care professionals regarding the safety of aspirin use in pregnancy. Those concerns
were magnified by a warning printed on aspirin packaging inserts against aspirin use in
pregnancy. Women were particularly worried about the consequences of aspirin use to
themselves and their unborn babies. Further, women made a clear distinction between
folic acid, iron, vitamin D and aspirin by attributing status of essential nutrients
needed to ‘help the baby’ to folic acid, and vitamin D and the status of ‘medication’ to
aspirin.
This highlights important domains: ‘Environmental context and resources’ in particu-
lar related to organisational culture and climate within the NHS, ‘Beliefs about conse-
quences’ build upon limited knowledge and the observations of other health care
professionals’ reaction to aspirin prescription requests (‘aspirin might be bad for me
and baby as different HCPs give me different messages’), lack of identification with a
person that is at risk of pre-eclampsia and unrealistic optimism. All these can therefore
lead to lower levels of adherence to aspirin.
Adherence to aspirin seemed to be very sensitive to changing contexts during the
pregnancy. Expected and unexpected ‘physiological’ changes change in emotional
status and family circumstances seemed to play an important role in both intentional
and unintentional non-adherence. At the time of these unexpected changes women
reported discontinuing the medication or taking it less regularly. ‘Salient events / critical
incidents’ related to the change in women’s behaviour related to aspirin adherence were
coded within ‘Environmental context and recourses’. Although ‘Salient events/critical
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incidents’, such as moving house, losing a close relative or developing a new medical con-
dition, seem to have compromised adherence to aspirin amongst interviewed women,
they could have provided an opportunity to intervene if seized by HCPs under Make
Every Contact Count initiative (Health Education England Making every contact
count, n.d.), however the lack of aspirin adherence reinforcement by those HCPs with
closer contact with the women was apparent and noted and interpreted by the women
as: ‘this is not that important otherwise I would be asked about this’.
Memory and attention were responsible for the unintentional non-adherence in this
cohort. Women stated that they suffered from cognitive overload during pregnancy along-
side mental and physical tiredness that in turn affected their ability to concentrate on the
task and remember to take the aspirin. This, in turn, prevented them from forming a habit.
Discussion
There is a plethora of literature reporting aspirin use in pregnancy both in terms of safety
and clinical effectiveness for the prevention of PE and other conditions (e.g. small for gesta-
tional age infant, stillbirth, and prematurity) (Bujold et al., 2009; Rolnik et al., 2017b;
Roberge et al., 2017b). However, the importance of adherence to aspirin has only recently
been recognised (Abheiden et al., 2016; Navaratnam, Alfirevic, Pirmohamed, & Alfirevic,
2017; Wright et al., 2017). There are only a few studies that explore factors and/or deter-
minants of non-adherence in pregnancy. In this study, we have identified important bar-
riers to aspirin adherence in pregnant women. Although women’s experience of pregnancy
is complex, the factors that influence aspirin adherence seem to fit a conceptual model of
Necessity – Concern Framework (Horne et al., 2013) which has shown that patients with
strong concerns about the intake of a specific medicine and weak beliefs about the necessity
of the medication are less likely to adhere to the prescribed treatment (Phillips, Diefenbach,
Kronish, Negron, & Horowitz, 2014). This is reflected in the way woman negotiate their
perception of necessity (knowledge, lack of identification with the risk factors, lack of
reinforcement) and concerns regarding their own and babies’ health as a result of
aspirin use during pregnancy (i.e. environmental barriers, beliefs about consequences).
Another factor that precluded women from adhering to aspirin preventative treatment
by both reducing the sense of necessity and increasing concerns, was the lack of easy
access to medication. This creates a non-verbal message suggesting potential safety con-
cerns amplified by suboptimal knowledge about aspirin amongst pregnant women.
Knowledge about the medicine and the condition lays a foundation stone for patients’
perceptions of the prescribed medicine both in obstetric and non-obstetric studies
(Harrold et al., 2012; Magadza, Radloff, & Srinivas, 2009; van der Wal et al., 2006).
Knowledge clearly has an important role and is a core part of another adherence-
related model, the model of ‘Informed adherence’ outlined by Michie et al. (Marteau,
Dormandy, & Michie, 2001).
Women’s inability to relate to their risk factors and to the role of a ‘medication taker’
has been described in several obstetric studies (Fenn, 2019; Gupton, Heaman, & Cheung,
2001). This inability to identify with someone who needs medication may be more pro-
nounced during pregnancy as pregnancy is often perceived as a natural/healthy state and
is less likely to be perceived as a time when medication is required. A recent publication
by van Montfort et al. suggests that personalisation of the risks may improve adherence
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to aspirin in pregnancy (van Montfort et al. 2020). This corresponds with wider work in
non-obstetric settings advocating for personalised adherence interventions (Petrie, Perry,
Broadbent, & Weinman, 2012).
Non-adherent women exhibited unrealistic optimism about their chance of developing
PE, presenting narratives that indicated that in order to enjoy pregnancy they were making
a decision not to think about risks; doing this led them to adopt an optimistic approach.
Women were using ‘external locus of control’ and ‘denial’ to cope with the stress of preg-
nancy risks instead of adopting active coping strategies. This approach to coping could
result from a sequence of events that women face during pregnancy; ‘booking’ processes
where there is a time lag between identification of the risk (stress) and the provision of
information regarding preventative strategies (coping), highlighting a need for appropriate
and timely support provision. In the UK midwives identify risk factors for PE as early as
8–9 weeks gestation. However, aspirin is not usually provided until weeks later when
women meet their obstetrician (typically at 12–14 weeks’ gestation). Therefore, women
may be aware that they are at increased risk but unable to progress with effective coping
for a significant period of time. This could be potentially overcome by the introduction
of preventative strategies at the time of risk identification. A recent study of factors influen-
cing adherence to aspirin in high-risk pregnancies by Shanmugalingam et al highlighted
the importance of improved communication to support understanding and allay concerns
about potential teratogenic effects of the medication (Shanmugalingam et al., 2020).
Aspirin has gained a ‘trustworthy’ status over decades of extensive use in the prevention
of hypertension and cardiac disease. The ‘trustworthy’ status of the drug has been
shown to facilitate adherence (Eborall & Will, 2011), however, our study suggests that
aspirin use during pregnancy is not yet trusted by pregnant women or some health care
professionals. Provision of timely education could be useful in the future as has been
shown to reduce concerns, improve understanding of the condition and medication and
subsequently improve adherence to the medication (Viswanathan et al., 2012).
The preventative nature of aspirin use in this group of women (i.e. it is given to
prevent the disease from developing rather than relieve the symptoms of the disease)
seems to reduce the perception of the necessity to take aspirin. Eborall et al. suggest
that in cases of a drug used to prevent disease, further legitimisation from a health
care professional is required (Eborall & Will, 2011). Women in our study received
mixed messages from health care providers and perceived an interdisciplinary conflict
regarding the use of aspirin in pregnancy. This was compounded by a warning against
the use of aspirin in pregnancy on the medication insert, resulting in insufficient legiti-
misation, despite receiving an aspirin prescription from an obstetrician.
Lin et al. have attempted to explain aspirin non-adherence in pregnancy using an
extended Theory of Planned Behaviour and suggested that the woman’s relationship
with her husband was important in mediating subjective norms and therefore affected
adherence (Lin et al., 2018). In our study women received ‘unconditional’ support
from their partners and significant others regarding medication, including the decision
to discontinue. Hence, we suggest social support may act as both a facilitator and a
barrier to adherence. Some women expressed clear independence in their decisions.
Although the relation between social support and adherence is not unidirectional in
intentional non-adherence, women that exhibited unintentional non-adherence found
partners instrumental in supporting routines and reminding women to take their
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medication. This seems to indicate that engaging a partner around the need to take pro-
phylactic aspirin would be relevant in supporting adherence.
The initial decision-making process is critical for adherence. In the case of PE there is also
the issue of a need to begin prophylaxis early in pregnancy (12 weeks) meaning that an
inability to make a timely decision can seriously compromise the effectiveness of the
aspirin treatment. We were able to demonstrate that in this complex process women
weigh their concerns regarding their baby’s and their own health against perceived necessity
of themedication while having little knowledge and professional support. Supporting women
with decision-making prior to treatment initiation, using principles of shared decision-
making, is more likely to lead to better engagement with therapy (Elwyn et al., 2010).
Adequate adherence is often associated with the use of strategies to overcome memory
and attention issues. Establishing routines and habits as well as introducing cues for
action can overcome unintentional non-adherence (Gardner, Lally, & Wardle, 2012;
Lally, van Jaarsveld, Potts, & Wardle, 2010; Michie et al., 2013). Stability of routines as
well as beliefs about medicines alongside good professional support has been highlighted
by Chambers et al. in a qualitative research of adherence in stroke survivors (Chambers
et al., 2011). Regular health care professional support and attention to medication adher-
ence is required in order to support women throughout the implementation of the
correct drug regimen, especially during any critical events, such as hospital admissions,
changes in woman’s physical environment or emotional status. Reinforcement is crucial
in order to establish and maintain a new behaviour. It is important to increase the oppor-
tunities to support women that persevere with the treatment as well as to provide women
with appropriate support.
Strengths and limitations
We were able to access a hard-to-reach population of non-adherent women not pre-
viously researched. We approached the study without a specific theoretical pre-con-
ception, instead, we used the TDF as an overarching framework and have arrived at a
set of constructs that are likely to explain aspirin adherence in pregnancy using an induc-
tive analytical process.
The obvious limitation of the study is that we only interviewed women who exhibited
non-adherence behaviours in pregnancy. Therefore, the study results reflect more bar-
riers and less facilitators of adherence. All participants were from a single tertiary hospital
in the North-East of England. It is possible that some of the barriers related to environ-
mental context and resources are characteristic of this part of the country and more needs
to be done to understand this.
It is important to highlight that women were interviewed at least 4 months after deliv-
ery of the baby and therefore there is the possibility of recall bias. The decision to inter-
view women postnatally was made in order to reduce unnecessary worry regarding the
effect of women’s non-adherence on their pregnancy outcome.
Conclusion
The study has shown that theoretical underpinning of Necessity-Concerns Framework
plays an important role in intentional non-adherent behaviours amongst pregnant
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women at risk of PE while deficiency in memory and attention was prevalent in uninten-
tional non-adherence.
We have identified important issues that present major barriers to adherence:
. Access to medication
. Perceived necessity of medication
. Beliefs about consequences of taking medication linked to the health professional
support and advise
Implications for clinical practice
. Clear pathways should be in place for women to obtain medication.
. It is necessary to improve knowledge, skills and to familiarise women with appropriate
behaviour regulations in order to improve adherence.
. Regular medication adherence support should be available for women throughout
pregnancy at the time of initiation of the treatment to support the decision-making
process and formation of habitual behaviour.
. Partners and other significant members of the women’s support system should be
involved in conversations about aspirin use in pregnancy.
. Adherence should be carefully reviewed at the time of any medical or social change.
Research recommendations
Further research is needed to investigate views of health care professionals around the use
of aspirin in pregnancy and perceived level of support provided to women. There is a scope
to conduct a wider investigation of determinants of non-adherence to include participants
from other regions in the country. Behaviour intervention needs to be developed, evaluated
and implemented to support adherence to aspirin amongst women at risk of PE.
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